XMS Serves as Financial Advisor to BioLife Solutions on its $75 Million Public Offering of Common Stock
July 2, 2020
CHICAGO, ILLINOIS, July 2, 2020 — XMS Capital Partners, LLC (“XMS”), a global, independent financial services firm providing investment banking, asset management and merchant banking services, announced that it served as financial advisor to BioLife Solutions, Inc. (NASDAQ: BLFS), on its $75 Million Public Offering of Common Stock.
This transaction represents BioLife’s first public offering of common stock since its shares were listed on the NASDAQ in 2014. BioLife anticipates using net proceeds from the offering for general corporate purposes, which includes, without limitation, potentially investing in or acquiring companies that are synergistic with or complementary to its technologies, and working capital. BioLife shares gained substantially during trading hours following the announcement.
XMS advised BioLife management on all aspects of the offering, including underwriter selection, transaction economics, and considerations regarding timing and execution. The offering welcomed participation from new, premier institutional investors to complement and diversify BioLife’s high-quality shareholder base. With the proceeds from the offering, BioLIfe will have the funds necessary for growth and to continue supplying leading cell and gene therapy customers with its class-defining bioproduction solutions.
On July 2, 2020, BioLife announced the pricing of its public offering of 5,175,000 shares of its common stock at a public offering price of $14.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to BioLife, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $75 million. The offering is expected to close on July 7, 2020, subject to the satisfaction of customary closing conditions. In addition, the underwriters have a 30-day option to purchase up to an additional 776,250 shares of common stock from BioLife at the public offering price, less underwriting discounts and commissions. Cowen, Oppenheimer and Stephens served as joint book-running managers for the offering.
About XMS Capital Partners
XMS Capital Partners, established in 2006, is a global, independent financial services firm providing investment banking, asset management and merchant banking services to clients. It has offices in Chicago, London and Boston.
XMS provides Involvement Banking™, which goes beyond transaction-oriented investment banking and focuses on delivering objective, value-added advice and custom tailored solutions to help clients achieve their strategic goals. It consistently creates value for its clients by giving them access to comprehensive, independent M&A, strategic advisory, financial restructuring, capital structure advisory and private capital advisory expertise.
XMS Capital Partners, LLC is a FINRA member and SIPC member. XMS Capital Partners (UK) Limited is authorized and regulated by the Financial Conduct Authority. For more information, please visit www.xmscapital.com.
About BioLife Solutions
BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools. BioLife’s tools portfolio includes its proprietary CryoStor® freeze media and HypoThermosol® shipping and storage media, ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, and Custom Biogenic Systems high capacity storage freezers. For more information, please visitwww.biolifesolutions.com, and follow BioLife on Twitter: @biolifesol.